Never miss an update from Yeda
Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide
Traceless covalent modification of proteins, including joining peptides or adding chemical groups, is extremely useful for numerous applications in chemical biology, protein chemistry, and biotechnology. A powerful tool currently used rely on Inteins, protein domains that auto-catalyze peptide bond formation. However, since inteins contain cysteine in their catalytic site, the reaction can only be made under reducing conditions, thus limiting the scope of proteins that can be modified. Prof. Pietrokovski and his collaborators at the University of Münster developed cysteine-less inteins that efficiently modify proteins under native and physiological conditions. They demonstrated their use with a full-length IgG antibody, an Fc fragment of an IgG, and nanobodies.
Background and Unmet Need
Modifying or joining proteins with other proteins/ peptides/chemical groups in a traceless manner is extremely useful for numerous applications. Existing solutions rely on Inteins, which are protein domains that auto-catalyze proteins’ posttranslational splicing reactions. Although this is a powerful tool that can be used both in vivo and in vitro, it can only be used under reducing conditions since it depends on one or two catalytic cysteines in the intein active site. This severely limits the scope of protein trans-splicing since it excludes proteins that are sensitive to reducing conditions, such as those containing critical disulfide bonds (i.e., antibodies).
The Solution
Prof. Shmuel Pietrokovski and his team developed cysteine-less (CL) split inteins that modify proteins efficiently under native and physiological conditions1.
Technology Essence
Inteins are protein domains that auto-catalyze protein-splicing of their flanking regions with a peptide bond. In protein trans-splicing, two parts of a split-intein can be used to ligate or cyclize polypeptides in a traceless manner.
The reaction is robust, can be performed in-vivo or in-vitro, using biologically or chemically synthesized peptides or proteins. The sequence of only 2-3 flanking amino acids is constrained. As shown in the figure below, the N and C terminal intein fragments (IntN & IntC) associate and fold into the active domain, thereby linking the flanking sequences with a peptide bond. All previously known split inteins only function in reducing conditions due to their use of one or two catalytic cysteines. In this invention, novel cysteine-less split inteins are capable of robust transsplicing at ambient temperatures and without the requirement of any chemical reducing or denaturation steps. This allows the preservation of disulfide bonds within the target protein. The use of this split intein was demonstrated for a full-length IgG, an Fc fragment of an IgG antibody, and two nanobodies as representatives of therapeutically relevant proteins. The reactions are high yielding (> 90%) at low to medium micromolar concentrations.
Figure 1 – Inteins mechanism of action
Applications and Advantages
References
Bhagawati M, Terhorst TME, Füsser F, et al. A mesophilic cysteine-less split intein for protein trans -splicing applications under oxidizing conditions. Proc Natl Acad Sci. 2019;116(44):22164-22172. doi:10.1073/pnas.1909825116 [1]
Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.
WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.
Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.
Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.
Yeda performs the following activities:
◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.
Our portfolio covers a broad spectrum of the natural sciences, including:
◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools
Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Yeda
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support